MX386832B - Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. - Google Patents
Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia.Info
- Publication number
- MX386832B MX386832B MX2018012221A MX2018012221A MX386832B MX 386832 B MX386832 B MX 386832B MX 2018012221 A MX2018012221 A MX 2018012221A MX 2018012221 A MX2018012221 A MX 2018012221A MX 386832 B MX386832 B MX 386832B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- hyperlipidemia
- angptl8
- angptl3
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para tratar a pacientes que padecen hiperlipidemia, en donde el paciente no responde, no es controlado adecuadamente por, o es intolerante al tratamiento con una terapia de modificación de lípidos estándar. Los métodos de la invención proveen la reducción de al menos un parámetro lipídico en el paciente administrando una cantidad terapéuticamente efectiva de un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a la proteína angiopoyetina 8 (ANGPTL8) en combinación con una cantidad terapéuticamente efectiva de un anticuerpo que se une específicamente a la proteína tipo angiopoyetina 3 (ANGPTL3). La combinación de un anticuerpo anti-ANGPTL8 con un anticuerpo anti-ANGPTL3 es útil en el tratamiento de enfermedades tales como la hipercolesterolemia, incluida la hipercolesterolemia familiar (HF), tanto la heFH como la hoHF, así como hiperlipidemia, hiperlipoproteinemia y dislipidemia, incluyendo hipertrigliceridemia, quilomicronemia, y para prevenir o tratar enfermedades o trastornos, para los cuales el metabolismo anormal de los lípidos es un factor de riesgo, tales como las enfermedades cardiovasculares.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319980P | 2016-04-08 | 2016-04-08 | |
| US201762453110P | 2017-02-01 | 2017-02-01 | |
| PCT/US2017/026679 WO2017177181A1 (en) | 2016-04-08 | 2017-04-07 | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012221A MX2018012221A (es) | 2019-02-13 |
| MX386832B true MX386832B (es) | 2025-03-19 |
Family
ID=58610026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012221A MX386832B (es) | 2016-04-08 | 2017-04-07 | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170291937A1 (es) |
| EP (1) | EP3439689B1 (es) |
| JP (1) | JP6964090B2 (es) |
| KR (1) | KR20180132843A (es) |
| CN (1) | CN109789194B (es) |
| AU (1) | AU2017248356A1 (es) |
| CA (1) | CA3020175A1 (es) |
| CY (1) | CY1124902T1 (es) |
| ES (1) | ES2896107T3 (es) |
| HR (1) | HRP20212028T1 (es) |
| HU (1) | HUE056878T2 (es) |
| IL (1) | IL262130A (es) |
| LT (1) | LT3439689T (es) |
| MD (1) | MD3439689T2 (es) |
| MX (1) | MX386832B (es) |
| PL (1) | PL3439689T3 (es) |
| PT (1) | PT3439689T (es) |
| RS (1) | RS62769B1 (es) |
| SI (1) | SI3439689T1 (es) |
| SM (1) | SMT202200016T1 (es) |
| WO (1) | WO2017177181A1 (es) |
| ZA (1) | ZA201806264B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| KR102456731B1 (ko) | 2016-03-03 | 2022-10-24 | 리제너론 파아마슈티컬스, 인크. | Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법 |
| CA3021884A1 (en) * | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with familial hypercholesterolemia |
| EA201991203A1 (ru) * | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| CA3080148A1 (en) * | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| CN113166760A (zh) * | 2018-11-23 | 2021-07-23 | 赛诺菲 | 用于抑制angptl8的新型rna组合物和方法 |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110613847B (zh) * | 2019-10-23 | 2022-02-11 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| CN111135303A (zh) * | 2020-01-17 | 2020-05-12 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| EP4095157A4 (en) * | 2020-01-22 | 2024-04-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-ANGPTL3 ANTIBODIES AND ITS USE |
| JP2023538522A (ja) * | 2020-08-07 | 2023-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
| US20230193271A1 (en) * | 2021-12-22 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors |
| CN114671943B (zh) * | 2022-04-29 | 2023-05-05 | 四川大学 | 一种鱼类摄食调控蛋白的制备和应用 |
| JP2025521114A (ja) * | 2022-05-16 | 2025-07-08 | シティ・オブ・ホープ | 抗ｃｄ８４抗体及びその使用 |
| CN115947779B (zh) * | 2022-08-10 | 2025-04-25 | 武汉安砥生物科技有限公司 | 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途 |
| WO2024130165A1 (en) * | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| WO2024227059A2 (en) * | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| CN119039435A (zh) * | 2024-09-21 | 2024-11-29 | 复旦大学附属儿科医院 | 一种抗angptl3人源化单抗及其应用 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
| CN119971041A (zh) * | 2025-02-05 | 2025-05-13 | 武汉大学 | 特异性降低胆固醇水平但不干扰甘油三酯代谢的分子靶点及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| JO3412B1 (ar) * | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US10071139B2 (en) * | 2014-10-03 | 2018-09-11 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
-
2017
- 2017-04-07 LT LTEPPCT/US2017/026679T patent/LT3439689T/lt unknown
- 2017-04-07 SI SI201730953T patent/SI3439689T1/sl unknown
- 2017-04-07 WO PCT/US2017/026679 patent/WO2017177181A1/en not_active Ceased
- 2017-04-07 EP EP17719107.9A patent/EP3439689B1/en active Active
- 2017-04-07 KR KR1020187032369A patent/KR20180132843A/ko not_active Abandoned
- 2017-04-07 CA CA3020175A patent/CA3020175A1/en active Pending
- 2017-04-07 AU AU2017248356A patent/AU2017248356A1/en not_active Abandoned
- 2017-04-07 MX MX2018012221A patent/MX386832B/es unknown
- 2017-04-07 HU HUE17719107A patent/HUE056878T2/hu unknown
- 2017-04-07 PL PL17719107T patent/PL3439689T3/pl unknown
- 2017-04-07 HR HRP20212028TT patent/HRP20212028T1/hr unknown
- 2017-04-07 US US15/482,499 patent/US20170291937A1/en not_active Abandoned
- 2017-04-07 ES ES17719107T patent/ES2896107T3/es active Active
- 2017-04-07 MD MDE20190190T patent/MD3439689T2/ro not_active IP Right Cessation
- 2017-04-07 SM SM20220016T patent/SMT202200016T1/it unknown
- 2017-04-07 CN CN201780035121.1A patent/CN109789194B/zh not_active Expired - Fee Related
- 2017-04-07 RS RS20211568A patent/RS62769B1/sr unknown
- 2017-04-07 PT PT177191079T patent/PT3439689T/pt unknown
- 2017-04-07 JP JP2018552824A patent/JP6964090B2/ja active Active
-
2018
- 2018-09-18 ZA ZA2018/06264A patent/ZA201806264B/en unknown
- 2018-10-04 IL IL262130A patent/IL262130A/en unknown
-
2019
- 2019-11-15 US US16/685,876 patent/US20200377583A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/571,286 patent/US20220127348A1/en not_active Abandoned
- 2022-01-10 CY CY20221100023T patent/CY1124902T1/el unknown
-
2024
- 2024-08-12 US US18/801,099 patent/US20250066463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180132843A (ko) | 2018-12-12 |
| WO2017177181A1 (en) | 2017-10-12 |
| ES2896107T3 (es) | 2022-02-23 |
| HUE056878T2 (hu) | 2022-03-28 |
| EP3439689B1 (en) | 2021-10-13 |
| US20220127348A1 (en) | 2022-04-28 |
| LT3439689T (lt) | 2021-11-10 |
| MX2018012221A (es) | 2019-02-13 |
| EP3439689A1 (en) | 2019-02-13 |
| CN109789194B (zh) | 2022-08-02 |
| ZA201806264B (en) | 2019-07-31 |
| US20170291937A1 (en) | 2017-10-12 |
| IL262130A (en) | 2018-11-29 |
| US20250066463A1 (en) | 2025-02-27 |
| PT3439689T (pt) | 2021-11-04 |
| CA3020175A1 (en) | 2017-10-12 |
| AU2017248356A1 (en) | 2018-10-25 |
| CY1124902T1 (el) | 2023-01-05 |
| SMT202200016T1 (it) | 2022-03-21 |
| CN109789194A (zh) | 2019-05-21 |
| US20200377583A1 (en) | 2020-12-03 |
| PL3439689T3 (pl) | 2022-01-31 |
| JP6964090B2 (ja) | 2021-11-10 |
| RS62769B1 (sr) | 2022-01-31 |
| SI3439689T1 (sl) | 2021-12-31 |
| MD3439689T2 (ro) | 2021-12-31 |
| HRP20212028T1 (hr) | 2022-04-01 |
| JP2019513751A (ja) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386832B (es) | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. | |
| MA44764B1 (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| MX2018010401A (es) | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| BR112017008093A2 (pt) | processos para tratamento de doenças oculares | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| PH12017500493A1 (en) | Combination therapy | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
| UY34137A (es) | ANTICUERPOS HUMANOS PARA LA PROTEINA 3 DE TIPO ANGIOPOYETINA HUMANA (hANGPTL3) | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
| NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| EA201990988A1 (ru) | Антитела против chikv и пути их применения |